Market Cap
US$120.0m
Last Updated
2019/09/17 00:30 UTC
Data Sources
Company Financials +
Executive Summary
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment of cancer.
Snowflake
Fundamentals
Excellent balance sheet with high growth potential.
Risks
- Sesen Bio has significant price volatility in the past 3 months.
Share Price & News
How has Sesen Bio's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
9.7%
NasdaqGM:SESN
1.1%
US Biotechs
1.1%
US Market
1 Year Return
-43.0%
NasdaqGM:SESN
-9.7%
US Biotechs
2.1%
US Market
SESN underperformed the Biotechs industry which returned -10.3% over the past year.
SESN underperformed the Market in United States of America which returned 2% over the past year.
Share holder returns
| SESN | Industry | Market | |
|---|---|---|---|
| 7 Day | 9.7% | 1.1% | 1.1% |
| 30 Day | 5.8% | -0.6% | 3.7% |
| 90 Day | -19.9% | -0.5% | 2.3% |
| 1 Year | -43.0%-43.0% | -8.9%-9.7% | 4.4%2.1% |
| 3 Year | -64.8%-64.8% | 7.5%3.8% | 47.0%37.4% |
| 5 Year | -89.9%-89.9% | 4.6%-0.4% | 61.6%43.8% |
Price Volatility Vs. Market
How volatile is Sesen Bio's share price compared to the market and industry in the last 5 years?
Simply Wall St News
6 hours ago | Simply Wall St
Those Who Purchased Sesen Bio (NASDAQ:SESN) Shares Five Years Ago Have A 90% Loss To Show For It1 month ago | Simply Wall St
What Kind Of Shareholders Own Sesen Bio, Inc. (NASDAQ:SESN)?3 months ago | Simply Wall St
Introducing Sesen Bio (NASDAQ:SESN), The Stock That Tanked 78%Valuation
Is Sesen Bio undervalued based on future cash flows and its price relative to the stock market?
>50%
Discount to future cash flow value
Intrinsic Value Based on Future Cash Flows
Sesen Bio's share price is below the future cash flow value, and at a moderate discount (> 20%).
Sesen Bio's share price is below the future cash flow value, and at a substantial discount (> 40%).
Price Based on Earnings
Sesen Bio is loss making, we can't compare its value to the US Biotechs industry average.
Sesen Bio is loss making, we can't compare the value of its earnings to the United States of America market.
Price Based on Expected Growth
Unable to calculate PEG ratio for Sesen Bio, we can't assess if its growth is good value.
Price Based on Value of Assets
Sesen Bio is overvalued based on assets compared to the US Biotechs industry average.
Next Steps
Future Growth
How is Sesen Bio expected to perform in the next 1 to 3 years based on estimates from 4 analysts?
32.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
Sesen Bio's revenue is expected to grow significantly at over 20% yearly.
Sesen Bio's earnings are expected to grow significantly at over 20% yearly.
Sesen Bio's revenue growth is expected to exceed the United States of America market average.
Sesen Bio's earnings growth is expected to exceed the United States of America market average.
Sesen Bio's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Earnings per Share Growth Estimates
Future Return on Equity
Unable to establish if Sesen Bio will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Next Steps
Past Performance
How has Sesen Bio performed over the past 5 years?
-7.3%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Sesen Bio does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
Unable to compare Sesen Bio's 1-year earnings growth to the 5-year average as it is not currently profitable.
Unable to compare Sesen Bio's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Return on Equity
It is difficult to establish if Sesen Bio has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
Return on Assets
It is difficult to establish if Sesen Bio has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
Return on Capital Employed
It is difficult to establish if Sesen Bio improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Next Steps
Financial Health
How is Sesen Bio's financial position?
Financial Position Analysis
Sesen Bio is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Sesen Bio's long term commitments exceed its cash and other short term assets.
Debt to Equity History and Analysis
Sesen Bio has no debt.
Sesen Bio has no debt compared to 5 years ago when it was 9.6%.
Balance Sheet
Low level of unsold assets.
Sesen Bio has no debt, it does not need to be covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Sesen Bio has sufficient cash runway for 2.2 years based on current free cash flow.
Sesen Bio has sufficient cash runway for 1.6 years if free cash flow continues to grow at historical rates of 45.1% each year.
Next Steps
Dividend
What is Sesen Bio's current dividend yield, its reliability and sustainability?
Dividend Yield and Payments Analysis
Unable to evaluate Sesen Bio's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Sesen Bio's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as Sesen Bio has not reported any payouts.
Unable to verify if Sesen Bio's dividend has been increasing as the company has not reported any payouts.
Current Payout to Shareholders
Unable to calculate sustainability of dividends as Sesen Bio has not reported any payouts.
Future Payout to Shareholders
Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
Next Steps
Management
What is the CEO of Sesen Bio's salary, the management and board of directors tenure and is there insider trading?
0.4yrs
Average management tenure
CEO
Thomas Cannell (57yo)
1.1yrs
Tenure
US$2,009,874
Compensation
Dr. Thomas R. Cannell, DVM, is President, Chief Executive Officer and Director at Sesen Bio, Inc. since August 7, 2018. He served as Chief Operating Officer of Orexigen Therapeutics, Inc. since June 8, 201 ...
CEO Compensation Analysis
Thomas's remuneration is higher than average for companies of similar size in United States of America.
Insufficient data for Thomas to compare compensation growth.
Management Age and Tenure
0.4yrs
Average Tenure
57yo
Average Age
The average tenure for the Sesen Bio management team is less than 2 years, this suggests a new team.
Board Age and Tenure
4.7yrs
Average Tenure
60.5yo
Average Age
The tenure for the Sesen Bio board of directors is about average.
Insider Trading
No 3 month open market individual insider trading information.
Ownership Breakdown
Management Team
Greg Verdine (60yo)
Co-Founder
- Tenure: 0yrs
Greg Adams (60yo)
Chief Scientific Officer
- Tenure: 0yrs
Glen MacDonald (68yo)
Chief Technology Officer
- Tenure: 0yrs
Chris Garcia
Co-Founder & Member of Scientific Advisory Board
- Tenure: 0yrs
Casey Weaver
Co-Founder & Member of Scientific Advisory Board
- Tenure: 0yrs
Kirstin Anderson (46yo)
Corporate Controller & Principal Accounting Officer
- Tenure: 0.08yrs
Thomas Cannell (57yo)
President
- Tenure: 1.1yrs
- Compensation: US$2.01m
Dennis Kim (50yo)
Chief Medical Officer
- Tenure: 0.8yrs
- Compensation: US$709.28k
Monica Forbes (43yo)
Chief Financial Officer
- Tenure: 0.08yrs
Erin Clark
Vice President of Corporate Strategy & Investor Relations
- Tenure: 0yrs
Board Members
Dan Lynch (61yo)
Director
- Tenure: 5.6yrs
- Compensation: US$130.30k
Wendy Dixon (64yo)
Chairman
- Tenure: 2.8yrs
- Compensation: US$257.57k
Patricia D'Amore (67yo)
Member of Scientific Advisory Board
- Tenure: 0yrs
Jane Pritchett Henderson (53yo)
Director
- Tenure: 5.6yrs
- Compensation: US$133.43k
Peter Campochiaro
Member of Scientific Advisory Board
- Tenure: 0yrs
Jay Duker (60yo)
Director
- Tenure: 4.7yrs
- Compensation: US$113.78k
Chris Garcia
Co-Founder & Member of Scientific Advisory Board
- Tenure: 0yrs
Reza Dana
Member of Scientific Advisory Board
- Tenure: 0yrs
Casey Weaver
Co-Founder & Member of Scientific Advisory Board
- Tenure: 0yrs
Thomas Cannell (57yo)
President
- Tenure: 1.1yrs
- Compensation: US$2.01m
Company Information
Sesen Bio, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Sesen Bio, Inc.
- Ticker: SESN
- Exchange: NasdaqGM
- Founded: 2008
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$120.000m
- Shares outstanding: 101.27m
- Website: https://www.sesenbio.com
Number of Employees
Location
- Sesen Bio, Inc.
- 245 First Street
- Suite 1800
- Cambridge
- Massachusetts
- 2142
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| SESN | NasdaqGM (Nasdaq Global Market) | Yes | Common Stock | US | USD | Feb 2014 |
| PCBK | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Feb 2014 |
Biography
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment of cancer. The company’s le ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/09/17 00:30 |
| End of Day Share Price | 2019/09/16 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.